Fiche centre
Fujian Medical University Union Hospital
Fuzhou — China
Essais liés14clinical trials
VilleFuzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06101940
Essais cliniques associés
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Giredestrant | Cancer | Phase 3 | NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | ACTIVE_NOT_RECRUITING |
| IPG11406 | Lupus | Phase 1/2 | NCT06717815 | Phase IIa Study for IPG11406 in Patients With Lupus Nephritis | COMPLETED |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| obinutuzumab (RO5072759) | Lupus | Phase 3 | NCT07767188 | A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) | NOT_YET_RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Skeletal muscle biopsy (residual specimen) | Myopathies | À vérifier | NCT06101940 | Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1) | ENROLLING_BY_INVITATION |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| Pozelimab + Cemdisiran | Myasthénie | Phase 3 | NCT05070858 | NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |